Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Editorials

Iron and Diabetes Revisited

  1. Sudhir V. Shah, MD1 and
  2. Vivian A. Fonseca, MD2
  1. From the 1University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas; and the
  2. 2Departments of Medicine and Pharmacology, Tulane University Health Sciences Center, New Orleans, Louisiana
  1. Corresponding author: Vivian A. Fonseca, vfonseca{at}tulane.edu.
Diabetes Care 2011 Jul; 34(7): 1676-1677. https://doi.org/10.2337/dc11-0700
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Iron is the most abundant transitional metal in the body. It has long been recognized that iron overload can increase the risk of diabetes, particularly in iron-overload states such as hemochromatosis and recurrent transfusions in diseases like thalassemia. Furthermore, a large body of epidemiological evidence suggests that an increase in dietary iron (as heme, mainly from meat and meat products) is associated with an increased risk of diabetes (1). In contrast, iron deficiency (over time one of the most common nutritional deficiencies in the world) may lower the risk of diabetes. Indeed, it has been suggested that recurrent phlebotomy may protect against diabetes (2), although there are no large multicenter, randomized controlled trials to support this hypothesis. In addition, iron has been implicated in the pathogenesis of renal disease including diabetic nephropathy (1).

Two articles in this issue of Diabetes Care add to this evidence and report that prepregnancy dietary heme iron intake is associated with an increased risk of diabetes. The association remains significant even after adjustment for a variety of factors known to be associated with gestational diabetes mellitus (GDM). Bowers et al. (3) studied participants in the Nurses' Health Study which has a robust dataset and fairly reliable information on dietary intake. Qiu et al. (4) have prospectively studied a similar cohort of over 3,000 pregnant women and used food frequency questionnaires to assess maternal diet. Not only was heme iron intake positively associated with GDM risk, nonheme iron may have been inversely related to such risk, although it is not statistically significant. Women who reported the highest heme iron intake experienced greater than a threefold increased risk of GDM.

How might increased iron intake lead to diabetes? Multiple mechanisms that link iron with abnormal glucose metabolism have been proposed, including β-cell dysfunction and insulin resistance, possibly mediated through oxidative stress (1). Animal studies suggest that iron impairs β-cell function by inducing oxidative stress as well as impairing mitochondrial function and may also decrease glucose uptake in muscle and adipose sites. Thus iron plays a role in several important steps in insulin action and glucose metabolism. There are very few pathophysiological studies that explore this association.

It is important to recognize that traditional methods of measuring iron may not be the best way to study the pathophysiological role of iron. For example, ferritin is often considered a marker of body iron stores but is an acute-phase protein that may be influenced by coincidental infections and, more importantly, in this setting, by the presence of low-grade inflammation associated with obesity. Moreover, ferritin itself does not participate directly in the oxidant reactions related to iron. Critical to iron's importance in biological processes is its ability to cycle reversibly between its ferrous and ferric oxidation states. This precise property, which is essential for its functions, also makes it very dangerous, because free iron can catalyze the formation of free radicals that can damage the cell. Thus, from a pathophysiological standpoint, it is important to measure iron pools that consist of chemical forms that can participate in redox cycling, often referred to as catalytic or labile iron (5–8). Baliga et al. (9) have previously demonstrated that there is a poor correlation between catalytic iron and total body iron stores. Thus measurement of catalytic iron may be important in the study of the association of iron and diabetes and its complications. Recent data suggest an increase in plasma and urinary catalytic iron in subjects with obesity without diabetes, as well as patients with diabetes-related complications and acute coronary syndromes (10–12).

The pathological effects of iron accumulation in tissue in iron-overload states are well known. What is new in the field is the recognition that iron plays an important role in the pathophysiology of disease in the absence of systemic iron overload (1). The concept of iron contributing to diabetes is supported by a few important recent animal studies. Cooksey et al. (13) have demonstrated that, in obese mice with type 2 diabetes treated with an iron-restricted diet as well as an iron chelator, there were improvements in glucose metabolism without causing overt iron deficiency. Thus, even at “normal” levels, iron exerts a detrimental effect on β-cell function that may be reversible with removal of iron, either through phlebotomy or possibly iron chelation (2). This concept lends itself to exploring phlebotomy or iron chelation as potential treatments for diabetes. Clearly research is needed to explore this approach in states of lesser overload with iron or indeed as a potential treatment of diabetes and prediabetes, particularly in those identified (by appropriate testing) as having either excess nutritional intake or overreactive iron associated with obesity. Studies in iron-overload states demonstrate an improvement in glucose metabolism with either of these modalities (2,14).

In the context of the two papers in this issue, it is possible that menstruation is protective for diabetes in premenopausal women and cessation of menses leads to some iron accumulation. Clinical trials are needed to determine whether phlebotomy or chelation of catalytic iron in women with GDM and adequate iron stores can improve the marked abnormalities seen in insulin secretion and action associated with this condition.

Acknowledgments

S.S. has received research support from National Institutes of Health grants 1UL1RR029884-01 and 1RC1DK086860-01 as well as a Veterans Affairs Merit Review. S.S. has a financial interest in Shiva Biomedical, LLC, which has licensed its technology to CorMedix, Inc. Diabetes research at Tulane University is supported in part by the Tullis–Tulane Alumni Chair in Diabetes. V.A.F. has previously been funded in a subcontract by a Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases on urinary catalytic iron in diabetes. He has served as a consultant to CorMedix, Inc. No other potential conflicts of interest relevant to this article were reported.

The authors thank Cindy Reid of the University of Arkansas for Medical Sciences for technical editing assistance.

  • © 2011 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Swaminathan S,
    2. Fonseca VA,
    3. Alam MG,
    4. Shah SV
    . The role of iron in diabetes and its complications. Diabetes Care 2007;30:1926–1933
    OpenUrlFREE Full Text
  2. ↵
    1. Fernández-Real JM,
    2. López-Bermejo A,
    3. Ricart W
    . Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348–2354
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bowers K,
    2. Yeung E,
    3. Williams MA,
    4. Qi L,
    5. Tobias DK,
    6. Hu FB,
    7. Zhang C
    . A prospective study of prepregnancy dietary iron intake and risk for gestational diabetes mellitus. Diabetes Care 2011;34:1557–1563
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Qiu C,
    2. Zhang C,
    3. Gelaye B,
    4. Enquobahrie DA,
    5. Frederick IO,
    6. Williams MA
    . Gestational diabetes mellitus in relation to maternal dietary heme iron and nonheme iron intake. Diabetes Care 2011;34:1564–1569
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Halliwell B,
    2. Gutteridge JMC
    . Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1–85
    OpenUrlCrossRefPubMedWeb of Science
    1. Gutteridge JMC,
    2. Rowley DA,
    3. Halliwell B
    . Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of ‘catalytic’ iron and anti-oxidant activity in extracellular fluids. Biochem J 1982;206:605–609
    OpenUrlAbstract/FREE Full Text
    1. Kruszewski M
    . The role of labile iron pool in cardiovascular diseases. Acta Biochim Pol 2004;51:471–480
    OpenUrlPubMedWeb of Science
  6. ↵
    1. Espósito BP,
    2. Epsztejn S,
    3. Breuer W,
    4. Cabantchik ZI
    . A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem 2002;304:1–18
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Baliga R,
    2. Ueda N,
    3. Shah SV
    . Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. Biochem J 1993;291:901–905
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Lele S,
    2. Shah SV,
    3. McCullough PA,
    4. Rajapurkar M
    . Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. EuroIntervention 2009;5:336–342
    OpenUrlCrossRefPubMed
    1. Thethi TK,
    2. Parsha K,
    3. Rajapurkar M,
    4. et al.
    Urinary catalytic iron in obesity. Clin Chem 2011;57:272–278
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Thethi TK,
    2. Rajapurkar MM,
    3. Walker PD,
    4. et al.
    Urinary catalytic iron in patients with type 2 diabetes without microalbuminuria—a substudy of the ACCORD Trial. Clin Chem 2011;57:341–344
    OpenUrlFREE Full Text
  10. ↵
    1. Cooksey RC,
    2. Jones D,
    3. Gabrielsen S,
    4. et al.
    Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab 2010;298:E1236–E1243
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Fernández-Real JM,
    2. Peñarroja G,
    3. Castro A,
    4. García-Bragado F,
    5. Hernández-Aguado I,
    6. Ricart W
    . Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002;51:1000–1004
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes Care: 34 (7)

In this Issue

July 2011, 34(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Iron and Diabetes Revisited
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Iron and Diabetes Revisited
Sudhir V. Shah, Vivian A. Fonseca
Diabetes Care Jul 2011, 34 (7) 1676-1677; DOI: 10.2337/dc11-0700

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Iron and Diabetes Revisited
Sudhir V. Shah, Vivian A. Fonseca
Diabetes Care Jul 2011, 34 (7) 1676-1677; DOI: 10.2337/dc11-0700
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Strategies to Reduce the Cost of Renal Complications in Patients With Type 2 Diabetes
  • Metformin Therapy During Pregnancy
  • Postprandial Glucose: Marker or Risk Factor?
Show more Editorials

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.